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Abstract: Exacerbations of COPD represent an important medical and health care problem. 
Certain susceptible patients suffer recurrent exacerbations and as a consequence have a poorer 
prognosis. The effects of bronchial infection, either acute or chronic, and of the inflammation 
characteristic of the disease itself raise the question of the possible role of antibiotics and anti-
inflammatory agents in modulating the course of the disease. However, clinical guidelines base 
their recommendations on clinical trials that usually exclude more severe patients and patients 
with more comorbidities, and thus often fail to reflect the reality of clinicians attending more 
severe patients. In order to discuss aspects of clinical practice of relevance to pulmonologists 
in the treatment and prevention of recurrent exacerbations in patients with severe COPD, a 
panel discussion was organized involving expert pulmonologists who devote most of their 
professional activity to day hospital care. This article summarizes the scientific evidence cur-
rently available and the debate generated in relation to the following aspects: bacterial and viral 
infections, chronic bronchial infection and its treatment with cyclic oral or inhaled antibiotics, 
inflammatory mechanisms and their treatment, and the role of computerized tomography as a 
diagnostic tool in patients with severe COPD and frequent exacerbations.
Keywords: COPD exacerbation, treatment, bronchial infection, anti-inflammatory treatment, 
antibiotics
Introduction
COPD is a progressive and heterogeneous chronic entity. One particular group of 
patients with COPD is highly susceptible to recurrent exacerbations that in turn increase 
the severity of the condition. At the same time, patients with greater functional severity 
are more likely to experience exacerbations.1 In most instances, the high frequency of 
exacerbations remains quite stable over time, and so this subset of patients is assigned a 
specific phenotype, “the frequent exacerbator phenotype”.1,2 Few studies have focused 
specifically on the treatment of patients with frequent exacerbations, and the standard 
recommendations for COPD in clinical practice guidelines – conventional treatment 
with bronchodilators (BDs) and inhaled corticosteroids (ICSs), and preventive mea-
sures such as influenza and pneumococcal vaccinations – may not be sufficient to 
completely prevent exacerbations in these challenging patients. It is not known why 
certain patients exhibit the frequent exacerbator phenotype, nor has it been established 
how far recurrent infections, defects in the individual’s own immune system, or the 
inflammatory nature of COPD may cause the presence of repeated exacerbations.3
The involvement of viruses and bacteria in exacerbations of COPD, and the 
possible roles of systemic and bronchial inflammation, and of the individual’s 
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defense mechanisms are receiving increasing attention. 
Anti-inflammatory therapy (mainly ICSs) may be beneficial 
in exacerbators, but it may also produce a degree of immu-
nosuppression and favor bacterial growth.4
Clinical trials provide scientific evidence of the efficacy 
of drugs and can help to guide the decision-making process, 
though in itself, the information they yield may not be suffi-
cient. Not all aspects of clinical practice with real-life patients 
are covered in the medical literature, and therefore, expert 
discussions regarding disease management in less frequent 
and more complex situations are relevant. In order to discuss 
aspects of clinical practice of importance to specialists in 
the treatment and prevention of recurrent exacerbations in 
patients with more severe COPD, a debate was organized 
involving expert pulmonologists who have devoted many 
years to patient care in the day hospital setting. This article 
summarizes the scientific evidence currently available, the 
points discussed, and the recommendations reached after 
the debate.
The role of infection in recurrent 
exacerbations of COPD and 
prevention strategies
The pathophysiology of COPD exacerbations is complex. 
From a clinical standpoint, not all exacerbations are similar, 
and they do not all respond to the same treatments. Cluster 
analyses of biomarkers capable of distinguishing between 
various etiologies of exacerbations have identified four main 
groups or phenotypes: 1) bacterial, 2) viral, 3) eosinophilic, 
and 4) pauci-inflammatory. The most common is the infec-
tious phenotype, which occurs in 85% of cases (55% bacte-
rial and 30% viral), followed by the eosinophilic phenotype 
(30%).5 Among the microorganisms involved in infectious 
exacerbations, the most common bacteria are Haemophilus 
influenzae, followed by Streptococcus pneumoniae and 
Moraxella catarrhalis. However, in patients with severe 
COPD who receive more antibiotic treatments or experi-
ence more severe exacerbations, Pseudomonas aeruginosa 
(PA) and Enterobacteriaceae are more frequently observed.6 
Regarding viral etiology, the most common is the rhinovi-
rus, followed by the parainfluenza virus, influenza, and the 
respiratory syncytial virus. Up to 25% of patients may have 
viral and bacterial coinfection.7
The evidence about the involvement of viruses in exac-
erbations of COPD is growing. In a human experimental 
model in which rhinovirus was inoculated in patients with 
COPD and healthy subjects, it was observed that patients 
with COPD had more severe respiratory symptoms, with a 
more pronounced deterioration in lung function and increased 
local inflammatory response.8 It has also been reported that 
patients with COPD inoculated with rhinovirus showed an 
exponential growth in bacterial load over the following days, 
especially H. influenzae, compared with smokers without 
COPD and nonsmokers. This suggests that rhinovirus infec-
tion may cause a change in the microbiome of patients with 
COPD or in their defense mechanisms, which facilitates 
subsequent bacterial infection.9 It has also been shown that 
patients with rhinovirus in their airways were more likely 
to suffer from exacerbations, a finding that underlines the 
impact of viral infection on the development of exacerba-
tions of COPD.7
An important factor in the recurrent bacterial exacerba-
tions is chronic bronchial infection (CBI). CBI is defined 
as the presence of potentially pathogenic microorganisms 
(PPMs) in the lower airways of patients with stable COPD 
and has been associated with both local and systemic inflam-
matory reactions.10 CBI can be identified by chronic produc-
tion of sputum, sometimes purulent, often associated with the 
presence of bronchiectasis and PPMs such as H. influenzae 
and PA in serial sputum cultures10,11 and has been related to 
loss of pulmonary function, worsening of health status, and 
increased frequency of exacerbations.10
In this group of patients, several prophylactic antibiotic 
regimens have been tested to assess their ability to prevent 
exacerbations by reducing the bacterial load and/or by 
preventing the acquisition of new strains, as well as other 
inflammatory and immunomodulatory mechanisms (Table 1). 
These regimens are used in patients who present a frequent 
exacerbator phenotype of infectious origin, despite appropri-
ate pharmacological and nonpharmacological treatment. The 
most common regimens are 1) continuous administration of 
macrolides, 2) intermittent quinolones, and 3) long-term use 
of inhaled antibiotics.12
Since the demonstration of the efficacy of macrolides 
in the treatment of diffuse panbronchiolitis, their use has 
been evaluated in many chronic respiratory diseases, and 
particularly in cystic fibrosis. In addition to their antimicro-
bial action, macrolides have a notable anti-inflammatory 
effect that decreases the bacterial load and virulence. They 
also reduce airway secretions and thus promote mucociliary 
clearance.13 Among the most important clinical trials of the 
efficacy of prolonged use of macrolides for the prevention 
of COPD exacerbations, the study by Albert et al compared 
the daily administration of 250 mg azithromycin versus 
placebo over a year in critically ill patients (but who were 
not necessarily selected for frequent exacerbations).14 
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Table 1 Clinical studies of antibiotic treatment for COPD in the stable phase
Study Design and treatment 
groups
Patient population Results
Gómez et al56 nonrandomized, open, 
comparative study of 
94 patients: 54 treated with 
azithromycin 500 mg/day 
for 3 days every 3 weeks 
from September to May, and 
40 receiving standard care
Mean age 67.6 years, recruited after 
admission due to exacerbation and 
a mean of six exacerbations in the 
previous year
Significant reduction in exacerbations and 
hospital admissions in the azithromycin group
Suzuki et al57 randomized, nonblind study in 
109 patients: 55 treated with 
erythromycin 200–400 mg/day 
and 54 in the control group, 
for 1 year
Mean age 70 years, mean FEV1 between 
1.3 and 1.47 L
Significant reduction in common infections 
and exacerbations in the antibiotic-treated 
group
Seemungal et al58 randomized, double-blind, 
placebo-controlled study. 
109 patients: 53 treated with 
erythromycin 250 mg twice 
daily, and 56 with placebo for 
1 year
Mean age 67.2 years, mean FEV1 50% Significant reduction in the frequency of 
exacerbations with antibiotics (35%, P=0.006). 
The mean time to first exacerbation was 271 
versus 89 days in the placebo arm (P=0.02). 
Significant reduction in the duration of the 
exacerbation with macrolide
Pomares et al59 retrospective study of 
24 patients with COPD 
treated with azithromycin 
500 mg three times per week 
for 1 year
Mean age 70.9 years, mean FEV1 32.2%, 
mean of 3.3 hospitalizations and seven 
exacerbations in the previous year
58.9% reduction in exacerbations and 61.2% 
reduction in hospitalizations compared to the 
previous year without macrolides
He et al60 randomized, double-blind, 
placebo-controlled study of 
36 patients: 18 treated with 
erythromycin 125 mg three 
times daily, and 18 with 
placebo
Mean age 69 years, mean FEV1 43% Significant reduction in the total number 
of cells in sputum and neutrophil elastase. 
Significant reduction (44%) in the relative risk 
of exacerbation with antibiotics. Significant 
delay in time to first exacerbation with 
macrolide
Blasi et al61 Open, randomized, 
noncontrolled study of 
22 patients with COPD and 
tracheostomy: 11 receiving 
azithromycin 500 mg 3 days 
per week for 6 months, and 11 
in the usual care group
Mean age 72 and 73 years. no 
information on lung function. 91% and 
73% were colonized
Time to first exacerbation was significantly 
longer with the macrolide. Hazard ratio for 
the first exacerbation associated with usual 
care was 5.41 (95% CI: 1.67–17.5). Significant 
reduction in hospitalizations with azithromycin
Albert et al14 randomized, double-blind, 
placebo-controlled clinical trial 
in 1,142 patients: 570 received 
azithromycin 250 mg daily, and 
572 received placebo
Mean age 66 years. Mean FEV1 39%–40%; 
.50% had required hospital visits for 
exacerbation in the previous year
Significantly reduced risk of exacerbations 
with azithromycin (P,0.001). Median 
time to first exacerbation was significantly 
prolonged: 174 days with placebo and 266 
with macrolide. Hazard ratio for time to first 
exacerbation was 0.71 (95% CI: 0.61–0.83; 
P,0.001)
Uzun et al16 randomized, double-blind, 
placebo-controlled clinical study 
in 92 patients with COPD: 
47 treated with azithromycin 
500 mg 3 days a week for 
1 year, and 45 with placebo
COPD with at least three exacerbations 
in the previous year. No significant 
bronchiectasis
Significant reduction (42%) in the rate of 
exacerbations in the azithromycin group 
compared to placebo
Sethi et al17 randomized, double-blind, 
placebo-controlled study of 
1,157 patients: 573 received 
moxifloxacin 400 mg once a 
day for 5 days, repeated cycles 
every 8 weeks for a total of six 
cycles, compared to placebo
Mean age 66 years, mean FEV1 40%, 
with at least two exacerbations in the 
previous year
Significant reduction (25%) of exacerbations 
with moxifloxacin (P=0.046). 45% reduction 
in exacerbations in patients with purulent/
mucopurulent sputum at the time of inclusion 
(Or =0.55, 95% CI: 0.36–0.84; P=0.006)
Abbreviations: FEV1, forced expiratory volume in 1 second; CI, confidence interval; OR, odds ratio.





Compared to placebo, treatment with azithromycin resulted 
in a significant decrease (27%) in exacerbation frequency 
and significantly prolonged the time to first exacerbation. 
Interestingly, in a responder analysis, azithromycin had 
less effect on patients who were active smokers.15 Adverse 
events with azithromycin have also been reported, such as 
an increase in the proportion of nasopharyngeal colonization 
by macrolide-resistant pathogens and a higher frequency of 
hearing disturbances, among others.14 In the study by Albert 
et al, because the presence of microorganisms in sputum at 
the end of treatment was significantly lower in the macrolide 
group (despite the higher proportion of resistant pathogens 
in these patients), their absolute numbers were lower than 
in the placebo group, and so it is unclear whether long-term 
use of macrolides does indeed lead to a global increase in 
resistance. Another important study compared treatment with 
500 mg of azithromycin 3 days per week for 1 year versus 
placebo, and included patients with COPD who had at least 
three exacerbations in the previous year and did not present 
significant bronchiectasis. The results were also positive and 
showed a significant reduction (42%) in the rate of exacerba-
tions with azithromycin compared with placebo.16
The PULSE study compared the administration of six 
5-day cycles of moxifloxacin (400 mg) every 2 months for 
1 year compared to placebo.17 This study included patients 
with the frequent exacerbator phenotype and chronic bronchi-
tis who had had at least two exacerbations in the previous year 
and were not colonized by PPMs resistant to moxifloxacin 
(specifically, resistant PA or Stenotrophomonas). Treatment 
with moxifloxacin reduced the risk of exacerbations by 25% 
overall and by 45% in patients who had purulent sputum 
at baseline (ie, those with probable CBI). No increase was 
observed in bacterial resistances to antibiotics, and no serious 
adverse events due to the treatment were recorded.17
In summary, the choice of long-term antibiotic therapy 
should carefully evaluate the advantages and disadvantages. 
Long-term antibiotic therapy provides an additional benefit 
in the control of exacerbations in selected patients, but it may 
also have important side effects, and the possible develop-
ment of resistance must always be borne in mind.12 In this 
regard, the Spanish COPD Guidelines (Spanish acronym 
GesEPOC) provide recommendations on the long-term use 
of antibiotics. Macrolides may be indicated in patients with 
frequent exacerbations requiring multiple courses of antibiot-
ics despite optimized treatment, especially in patients who 
also have bronchiectasis on chest computed tomography (CT) 
and/or isolation of PA in sputum.18 Liver function should 
be monitored before and during treatment; atypical 
mycobacterial infections should be ruled out by specific 
culture, as well as the presence of arrhythmias through an 
electrocardiogram. Finally, macrolide use should be avoided 
in patients with hearing problems. The proposal is a regimen 
of 500 mg of azithromycin three times a week in the winter 
months. The long-term use of quinolones must be even more 
restrictive because of the possible development of quinolone 
resistance and the caveat that CBI due to quinolone-resistant 
PPMs (especially PA or Stenotrophomonas) must be previ-
ously ruled out. The guidelines recommend that prescription 
should take place at reference centers under strict clinical and 
microbiological control.18
The role of inflammation and 
its treatment in frequent COPD 
exacerbations
Inflammation is important not just in the context of COPD 
exacerbations but in the stable phase as well. Both the 
GOLD document and the GesEPOC guideline state that 
the pulmonary inflammation is an essential component of 
the disease, which develops as an abnormal response to 
certain harmful particles, especially tobacco smoke, and 
depending on the genetic background of each individual.12,19 
Inflammation develops not only in the airways but also 
systemically and may be associated with comorbidities 
that worsen the prognosis. The inflammatory process is 
modulated by various pathological mechanisms involving 
cells such as CD8+ T lymphocytes, especially macrophages 
and neutrophils.3
Initially, exposure to certain noxious agents such as 
cigarette smoke, viruses, or bacteria causes a response that 
is mediated basically by macrophages and neutrophils in the 
bronchial tree with the release of proinflammatory cytokines. 
This eventually causes a narrowing of the airway due to col-
lagen deposition, an increase in the lymphoid follicles in the 
bronchial wall, thickening of the epithelial basal membrane, 
and release of an inflammatory exudate with reduced lumen.20 
Depending on the pathways involved in the inflammatory 
process, the initial participation of macrophages and dendritic 
cells gives rise to the activation of monocytes, fibroblasts, 
CD8+ T cells, and neutrophils; this triggers, to a greater or 
lesser extent, the processes of bronchiolitis, fibrosis, emphy-
sema, and/or mucus hypersecretion that can be found in 
patients with COPD.21 However, it has also been reported 
that some patients with COPD develop an inflammatory 
process caused by cytokines (mainly interleukins (ILs)-4 
and -5), through the involvement of eosinophils, thus defining 
a specific feature of these patients.22
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Inflammation of the airways is associated with disease 
severity and exacerbation episodes. Thus, patients with major 
airway obstruction and recurrent exacerbations are affected 
by greater local inflammation.23 Furthermore, inflammation 
(measured by the percentage of neutrophils in sputum) has 
been associated with a greater loss of lung function, and so 
these inflammatory mechanisms are also related to disease 
progression.24 When the inflammatory mediators involved 
in exacerbations of COPD are analyzed and compared with 
those identified in asthma, the participation of the cell groups 
is different; in COPD, macrophages, neutrophils, and CD8+ 
T cells are primarily involved, while in asthma, mast cells, 
eosinophils, and CD4+ T lymphocytes predominate, with a 
lower representation of macrophages. The proinflammatory 
cytokines and their effects at the tissue level also differ: the 
main protagonists are leukotriene B4, IL-8, tumor necrosis 
factor-α, and reactive oxygen species in COPD, and leu-
kotriene D4, histamine, IL-4, IL-5, and reactive oxygen 
species in asthma. The effects of this inflammation become 
apparent mainly in the peripheral airways in patients with 
COPD, with destruction of lung parenchyma, fibrosis, and 
squamous metaplasia. In patients with asthma, basically the 
whole airway is affected, with mild fibrosis and thickening 
of the basal membrane, and response to steroid treatment is 
better than in COPD.25
Despite these clear differences between asthma and 
COPD, a group of patients share the characteristics of 
both diseases. This situation may affect their evolution and 
response to treatment. Recently, this syndrome has been 
termed the asthma–COPD overlap syndrome (ACOS), and 
the typical patient is an asthmatic long-term smoker who has 
developed an incompletely reversible airflow obstruction.26 
A group of Spanish experts established diagnostic criteria 
for ACOS in patients with COPD, which were implemented 
in the GesEPOC guideline.18,27 The criteria were previous 
history of asthma in a patient with COPD, reversibility of 
the obstruction, and eosinophilic or Th2 inflammation that 
responds to the use of ICSs.28 The percentage of patients 
with COPD who belong to the ACOS group depends on 
the criteria used for diagnosis but ranges between 10% and 
25%.26 Currently, there are no conclusive data on the use 
of biomarkers for the diagnosis of ACOS, but a prior diag-
nosis of asthma in patients with COPD can be a key factor 
for selecting patients who require further study in order to 
identify this syndrome.29,30
The treatment of inflammation in patients with COPD and 
the frequent exacerbator phenotype is outlined in guidelines, 
which recommends a series of drugs for controlling the 
inflammatory mechanisms of the disease. Among the most 
important are ICSs, which, when used in combination with 
long-term beta-2 agonists (LABAs), have proven effective 
in improving symptoms and lung function and in reducing 
exacerbations.18,19,31 However, ICS therapy is associated 
with several adverse effects, including an increased risk of 
pneumonia.31,32
The use of corticosteroids reduces sputum eosinophilic 
inflammation.33 For this reason, patients with ACOS, who 
usually present with sputum eosinophilia, may respond well 
to ICS treatment.34 The GesEPOC guideline recommends the 
early use of ICS in patients with ACOS and adjustment of the 
dose in accordance with clinical controls, lung function, and 
if possible, the presence of sputum eosinophilia.18
The use of ICSs in COPD is widespread and sometimes 
does not follow the approved indications.32 In these cases, 
their withdrawal should be considered. However, the data 
from the COPE study showed that the interruption of ICS in 
patients with moderate-to-severe COPD may accelerate the 
recurrence of exacerbations and increase the rate of decline 
in forced expiratory volume in 1 second (FEV
1
) leading to a 
significant deterioration in quality of life.35 Another recent 
study in a group of patients with severe COPD with at least 
one exacerbation in the previous year and receiving treatment 
with triple therapy (LABA/ICS + long-acting anticholinergic) 
compared the effect of withdrawing ICS and continuing 
triple therapy over a follow-up period of 12 months. In this 
study, the risk of exacerbation did not increase in patients 
who discontinued treatment with ICS.36 However, the group 
that abandoned ICS therapy showed a loss of lung function 
(43 mL of FEV
1
 at week 52), although this loss was below 
the threshold considered clinically significant and was not 
accompanied by a significant impairment in quality of life 
or dyspnea.36
Roflumilast is a phosphodiesterase-4 inhibitor which also 
has an anti-inflammatory effect, and is indicated for patients 
with severe COPD with chronic bronchitis and frequent 
exacerbations.18 In a recent 1-year study, roflumilast was 
effective in reducing severe exacerbations requiring hospital-
ization in patients receiving treatment with LABA/ICS, and 
even in the 70% receiving triple therapy with LABA/ICS + 
long-acting anticholinergic.37 In real life, however, tolerance 
of roflumilast is worse than in clinical trials, and so its use 
in patients with severe COPD may be limited by adverse 
events.38 The most common side effects are gastrointestinal 
disorders and weight loss.
Finally, although it is not an anti-inflammatory treatment, 
the possibility that respiratory rehabilitation may play a role 





in the control of exacerbations in patients with COPD has also 
been considered. There is some evidence that rehabilitation 
may decrease the rate of readmissions and improve symp-
toms and patients’ quality of life.39 Respiratory rehabilitation 
improves the degree of dyspnea and lengthens the time until 
the next exacerbation in patients with a high exacerbation 
risk.40 Rehabilitation helps patients to increase their daily 
physical activity, which is a prognostic factor in COPD.41
Discussion
Does Ct have a role in the evaluation of 
patients with frequent exacerbations?
Some severe patients continue to suffer exacerbations despite 
receiving the best BD and anti-inflammatory treatment avail-
able. In these cases, it is believed that infection plays a major 
role in the recurrence of exacerbations. In some patients with 
COPD and multiple exacerbations, ineffective mucociliary 
clearance facilitates PPM colonization of the airways, caus-
ing inflammation. This is followed by the manifestation of 
increased respiratory symptoms and an increase in the rate 
of exacerbations, which constitutes the CBI.10,42
High-resolution chest CT scans indicate the presence 
of bronchiectasis in up to 60% of patients with COPD and 
FEV
1
 ,50%, and bronchiectasis in COPD is associated with 
worse prognosis.11,43
Therefore, CBI and the presence of bronchiectasis 
increase the risk of exacerbations and aggravate COPD out-
come. Today, several scoring systems have been validated for 
characterizing and assessing the extent of bronchiectasis, but 
since not all the published studies use the same criteria, their 
interpretation is difficult. The most widely recommended 
system is the one proposed by Smith et al that quantifies the 
extent of bronchiectasis in each lobe, with an overall score 
between 0 and 24 points.44
All participants in the expert panel discussion agreed 
that in patients with frequent exacerbations, the presence of 
bronchiectasis should be assessed with high-resolution chest 
CT, as its identification is associated with worse prognosis 
and with an increased risk of recurrent exacerbations and 
CBI. Patients with bronchiectasis and COPD exacerbations 
should be treated for COPD and also according to the cur-
rently approved bronchiectasis protocols and standards of 
treatment.45
Should active attempts be made to 
isolate PA and identify CBI in cultures?
The patients with COPD and frequent exacerbations who 
present the highest degree of complexity are those with 
greater airflow obstruction and respiratory infections due to 
unusual PPMs such as PA, which is associated with increased 
mortality.10,46,47 Some of the known risk factors for infection 
by PA in COPD are shown in Table 2. Clinical guidelines 
recommend antipseudomonal empirical treatment in patients 
with very severe COPD (FEV
1
 ,30%) who have received 
antibiotics in the last 3 months or four courses of antibiotics 
over the last year, or in patients with prolonged treatment 
with systemic corticosteroids.48 However, bronchiectasis is 
not included within these risk factors related to PA, although 
its prevalence may be up to 60%.
In a recent study carried out in a respiratory day unit 
and aimed to describe the characteristics and risk factors for 
PA infection in severe COPD (FEV
1
 ,50%) and frequent 
exacerbations followed up over ~3 years, bronchiectasis 
was recorded in 47% of patients, and PA was isolated in 
35% of them during exacerbations. Furthermore, the main 
risk factor associated with PA infection was the extent of 
bronchiectasis, followed by the number of previous courses 
of antibiotics.49 When comparing patients with and without 
isolated PA, no differences in lung function, BODE index, 
or comorbidities were found; however, patients with PA had 
longer hospital stay, greater need for oral corticosteroids, and 
increased mortality.49
Regarding bronchial colonization (or CBI) by PA in this 
same cohort and applying the classic criteria of three isola-
tions or more separated by at least 1 month over a period 
of 6 months, 12% of patients with an initial isolation of 
PA eventually presented CBI due to this microorganism, 
Table 2 risk factors for Pseudomonas aeruginosa infection in 
COPD
Study Risk factors
Allegra et al62 FEV1 ,35%
Eller et al63 FEV1 ,35%
Pretreatment with antibiotics
Miravitlles et al6 FEV1 ,50%
Lode et al64 FEV1 ,35%
Use of systemic corticosteroids
Antibiotics in the previous 3 months
Monsó et al65 Low FEV1
Use of oral corticosteroids
Antibiotics in the previous 3 months
Protective effect of influenza vaccine
García-Vidal et al66 Use of systemic corticosteroids
High BODE index
Hospital admission in the previous year
Previous isolation of P. aeruginosa
Gallego et al49 Presence and extent of bronchiectasis
Prior exposure to antibiotics
Abbreviation: FEV1, forced expiratory volume in 1 second.
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as demonstrated by a pattern of clonal persistence of the 
initially isolated PA strain. The same strain of PA was not 
isolated again in the remaining patients; some acquired new 
strains of PA and eradicated them during the follow-up, and 
others showed patterns of clonal persistence or alternation 
but did not fulfill the criteria for CBI. In those with CBI, it 
was not associated with the extent of bronchiectasis, nor 
was any clonal transmission observed between patients with 
COPD.49 Among other important aspects to bear in mind 
in clinical practice are the PA morphotypes, since mucoid 
morphotypes are associated with resistance mechanisms and 
virulence, while normal or nonmucoid morphotypes are not. 
This distinction may be clinically relevant.50
As expected, culture-independent techniques, such 
as studies of the bronchial microbiome in patients with 
severe COPD, showed that patients colonized by PA have 
a higher prevalence of the genus Pseudomonas compared 
with patients not colonized by PA, as do conventional 
microbiological cultures. In these cases, the rest of the 
bronchial microbiome was similar in patients colonized 
and noncolonized by PA. Moreover, patients with and with-
out colonization by PA had a similar microbiome during 
exacerbations.51
In view of the above, participants in the expert panel 
discussion agreed that active attempts should be made to 
isolate PA in serial sputum cultures in patients with severe 
COPD and frequent infective exacerbations.
In the light of the above, which antibiotic 
should be administered to a patient 
colonized with PA who has an infectious 
exacerbation?
The first point to consider is the pattern of PA resistance to 
commonly used antibiotics. If CBI is due to a quinolone-
sensitive PA, the best option would be oral ciprofloxacin at 
high doses (750 mg bid) over a period of 2–3 weeks. The 
use of parenteral antibiotics with antipseudomonal activity 
should be reserved for severely ill patients or those with prior 
treatment failures. It should also be considered that not all the 
exacerbations in a patient colonized by PA are caused by 
this microorganism. In fact, ~50% are due to usual bacteria; 
therefore, microbiological assessment of exacerbations is 
important in order to guide the choice of the most appropriate 
antibacterial agent. Another empirical oral treatment option 
in this situation is the use of high-dose levofloxacin (500 mg 
bid), which has good activity against usual microorganisms 
such as H. influenzae and S. pneumoniae and acceptable 
activity against quinolone-sensitive PA.48
Is inhaled antibiotic therapy ever 
indicated in patients with COPD?
Inhaled antibiotics represent a very attractive therapeutic 
option, since these drugs may achieve a high concentration in 
the airways with low systemic exposure. As a consequence, 
the side effects are minor and relatively well tolerated, the 
most common being wheezing and local irritation, which 
are easily controlled with BDs. This therapy is indicated in 
cystic fibrosis and also in noncystic fibrosis bronchiectasis, 
but scientific evidence in patients with COPD is scarce. 
A previous small study assessing the effect of nebulized 
tobramycin twice a day for 14 days in patients with severe 
COPD colonized by multiresistant PA found reductions in 
local inflammation and bacterial load (and even eradication 
in some patients), and finally a 42% reduction in severe 
exacerbations after 6 months of treatment.52 Phase II clinical 
trials of the use of inhaled antibiotics in CBI due to PA in 
patients with COPD are currently underway.
The expert panel did not reach agreement on this point. 
At present, the use of inhaled antibiotics in patients with 
COPD and CBI is not indicated because their efficacy has not 
been demonstrated and the clinical experience is very limited. 
However, in a pilot study conducted at a day hospital unit 
specialized in patients with severe and very severe COPD 
and a high risk of exacerbations by PA, tolerance to treatment 
with inhaled nebulized colimycin was good, with an adher-
ence of 88%. A preliminary analysis also recorded a signifi-
cant reduction in the number of exacerbations and emergency 
visits during a year of follow-up in these patients.53
Does it make sense to treat respiratory 
viruses if a viral exacerbation is 
suspected?
There was consensus among participants that the only viral 
infection associated with COPD exacerbation that can be 
treated is influenza A (H1N1), for which a specific antiviral 
agent and a hospital-based diagnostic test are available. 
Antiviral treatment should be started early, since the viral 
load has been reported to remain high in the first 7 days after 
onset of symptoms.54
Are antipneumococcal and influenza 
vaccines recommended for all patients 
with COPD?
In the case of antipneumococcal vaccine, the use of the con-
jugate vaccine with 13 serotypes is recommended because 
patients with COPD are a risk group for pneumococcal 
infection.55 However in countries such as Spain, the cost of 





the vaccine is not reimbursed for patients with COPD by 
the public health insurance. The only exception are those 
with an additional condition, such as the continued use of 
corticosteroids or other pathology associated with immuno-
suppression. Annual influenza vaccination is indicated for 
all patients with COPD.
However, all authors agreed that having an effective 
vaccine against H. influenzae would probably be much more 
useful than the pneumococcal vaccine, given the frequency of 
this microorganism as the cause of exacerbations of COPD.
What is the recommendation for the use 
of oral azithromycin – only in the winter 
months, or throughout the year?
In clinical practice, the use of azithromycin in COPD has 
followed the example of cystic fibrosis, that is, continuous 
administration throughout the year. Its use in the winter 
months is recommended in the GesEPOC guidelines to try to 
reduce antibiotic exposure without loss of effectiveness, but 
no clear evidence exists in favor of this strategy.18 It has to 
be considered that the anti-inflammatory effect of macrolides 
may take several weeks to appear; in consequence, therapy 
should be initiated before the onset of winter.
The use of azithromycin should be considered when the 
patient continues to experience infectious exacerbations 
despite optimal respiratory treatment. In these circumstances, 
the benefits appear to outweigh the risks, although close 
monitoring of the patient is crucial to detect early adverse 
effects associated with the use of the macrolide.12 Most 
of the participants in the expert panel prescribe treatment 
with azithromycin in patients with recurrent exacerbations 
(usually more than three in 1 year). Some discontinue the 
treatment in summer, but others maintain it throughout the 
year if the patient does not show side effects.
Should a patient who has required 
systemic corticosteroids for a single 
exacerbation start ICS treatment in 
order to prevent further exacerbations?
At present, there is not enough evidence to support initiating 
ICS treatment after a single exacerbation and maintaining 
it chronically in all cases. Although ICSs have been shown 
to reduce exacerbations in patients with COPD, they are 
not exempt from side effects.31 In the daily clinical practice 
of most of the participants in the discussion, ICS treatment 
is usually administered only temporarily in these cases or 
at progressively reduced doses, depending on the severity 
of airflow obstruction or the risk of adverse events in each 
particular patient.
What role does systemic inflammation 
play in the prognosis of these patients?
The existing evidence suggests that systemic inflamma-
tion may play a key role in the development of various 
comorbidities associated with COPD, and may thus affect 
patient prognosis. However, all participants agreed that 
there is no specific treatment aimed at controlling systemic 
inflammation in COPD.
What is the experience of the efficacy 
and safety of roflumilast?
All expert panel participants reported that roflumilast was 
poorly tolerated by a high percentage of patients, who 
develop gastrointestinal side effects in spite of the use 
of progressive doses or dose reduction in the case of an 
adverse event. However, patients who tolerate roflumilast 
will benefit from it, with a reduction in the frequency of 
exacerbations and slight increase in lung function. There-
fore, roflumilast should be tested in patients in whom it is 
indicated, that is, those with severe COPD with chronic 
bronchitis and frequent exacerbations despite maximum 
inhaled treatment.
Even though the use of roflumilast is recommended in 
the main clinical practice guidelines, experience with its use 
as an anti-inflammatory agent is not comparable with that 
of ICS; far more is known of the safety profile of ICSs and 
their long-term benefits.
According to current guidelines, patients 
with COPD without exacerbations 
should not use ICS, but what about those 
with chronic local inflammation and the 
resulting loss of lung function?
It has been reported that patients with COPD present sus-
tained lung inflammation even in the stable state and may 
suffer a loss of lung function after ICS withdrawal.
The consensus among participants was that the decision 
to withdraw ICSs should be individualized, after weighing up 
the risk of pneumonia, the possible loss of lung function, and 
other adverse effects, against their efficacy in reducing the 
frequency of exacerbations. During the process of withdrawal 
of ICS, patients must be closely monitored.32
An alternative is to reduce the dose of ICS in patients 
with COPD without exacerbations, who are receiving high 
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doses despite no particular benefits of the high doses of ICS 
over lower doses in COPD have been reported.
Conclusion
Inflammatory mechanisms play a key role in COPD, both 
in the progression of the disease and during exacerbations. 
The presence of inflammatory cells (primarily neutrophils 
and macrophages) increases with the severity of disease 
and contributes to the exacerbations and progressive loss 
of lung function.
ACOS is the term used to describe a subgroup of patients 
with COPD who present an asthma-like inflammation.
The most widely used anti-inflammatory agent in COPD 
is ICS. A better understanding of the different phenotypes of 
COPD should help to establish a more rational use of ICS. 
There are a variety of exacerbation phenotypes, which remain 
relatively stable over time; bacterial and viral phenotypes 
are the most frequent. Viral infections cause up to 30% of 
exacerbations of COPD, and these infections may precipitate 
secondary bacterial infection. CBI is also associated with 
frequent exacerbations, affecting lung function and worsen-
ing quality of life.
Long-term antibiotic treatment is effective in reducing 
exacerbations in carefully selected patients with COPD. 
It should be considered as an add-on therapy in patients with 
severe COPD and frequent exacerbations of infectious origin, 
who require multiple courses of antibiotics despite optimal 
pharmacological and nonpharmacological treatment. However, 
the indication should always be individualized, the adverse 
effects monitored, and strict clinical controls performed.
Inhaled antibiotics are a promising alternative in patients 
with COPD with frequent exacerbations and CBI, particu-
larly in cases that do not respond to oral treatment or present 
significant adverse events. However, controlled studies are 
required to test their efficacy and safety and evaluate the 
possible development of antimicrobial resistance.
High-resolution chest CT is useful in patients with the 
frequent exacerbator phenotype for the diagnosis of bron-
chiectasis. In addition, serial sputum cultures will help to 
identify patients with CBI and specially when caused by 
unusual bacteria such as PA or Stenotrophomonas.
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